Fig. 6

Detailed binding of Runx1 to the promoters of target genes in the context of chondrocyte pathology. a Peak values of target genes in chondrocyte pathology were identified by using IGV analysis. The specific average peak values are shown in the right histograms. b Motif analysis based on Runx1-ChIP-seq (hommer) identified two sequences at the promoter regions of these target genes in the context of chondrocyte pathology. c Bioinformatics analysis indicated the specific locations of these two sequences in the promoters of the TAPT1, RIC1, and FGF20 genes. d ChIP-qPCR confirmed one binding site (−3 224 to −3 214) of Runx1 in the promoter of the TAPT1 gene. Strip diagrams from electrophoretic gels based on ChIP-qPCR products confirmed this result. e ChIP-qPCR confirmed another binding site (−1 094 to −1 086) of Runx1 in the promoter of the TAPT1 gene. Strip diagrams from electrophoretic gels based on ChIP-qPCR products confirmed this result. f ChIP-qPCR confirmed the binding site (−2 343 to −2 335) of Runx1 in the promoter of the RIC1 gene. Strip diagrams from electrophoretic gels based on ChIP-qPCR products confirmed this result. g ChIP-qPCR confirmed the binding site (−707 to −697) of Runx1 in the promoter of the FGF20 gene. Strip diagrams from electrophoretic gels based on ChIP-qPCR products confirmed this result. These results are based on at least three independent experiments (n = 3). All significance data presented in a, d, e, f, and g are based on two-tailed Student’s t-tests